Dongmei Zhou

Dongmei Zhou has a strong and diverse work experience in the pharmaceutical industry. Dongmei has held the role of Sr. Director at Bristol Myers Squibb since 2022. Prior to this, they worked as a Director at Turning Point Therapeutics starting in 2019. From 2017 to 2019, Dongmei served as an Associate Director / Sr Scientist at La Jolla Pharmaceutical Company. Before that, they held the position of Senior Principal Scientist at AstraZeneca/Ardea from 2007. Their responsibilities included developing methods and leading method validation for clinical studies, performing pharmacokinetic data analysis, and leading in-vitro ADME testing. Dongmei also has experience at Valeant Pharmaceuticals, where they served as an Associate Principal Scientist and Research Scientist. Their roles here involved developing LC-MS/MS methods for drug determination, profiling in-vitro or in-vivo metabolites, and developing high-throughput extraction and separation methods. Overall, Dongmei boasts a wealth of experience with a focus on method development and validation, pharmacokinetics, and ADME testing.

Dongmei Zhou completed their Bachelor of Science degree in Chemistry from Jilin University from 1989 to 1993. Dongmei then pursued further studies and earned their Doctor of Philosophy (Ph.D.) in Analytical Chemistry from the University of Tennessee, Knoxville, from 1993 to 1999.